Eli Lilly has reached an agreement to acquire Kelonia Therapeutics, a clinical-stage biotechnology company pioneering in vivo gene delivery, for up to $7 billion. Kelonia has developed a proprietary in vivo gene placement system (iGPS0) that uses specially engineered lentiviral-based particles designed to enter T-cells inside the body, allowing the patient’s own body to generate […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!